MedTrace Logo

Relationship Between Plasma Metabolome and the Efficacy of Systemic Glucocorticoid in AECOPD

NCT04710849 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-01-15

No results posted yet for this study

Summary

Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) significantly increases the mortality of the patients with COPD. Guidelines have recommended systemic glucocorticoid as regular treatment. Recently, evidences have shown that systemic glucocorticoid cannot not be benefit to all of the patients with AECOPD. Thus the problem that how the clinicians can screen the patients who can benefit from systemic glucocorticoid needs to be solved urgently.

Conditions

  • COPD
  • COPD Exacerbation Acute

Interventions

DIAGNOSTIC_TEST

Serum metabolic markers

Ultraperformance liquid chromatography / mass spectrometry (LC-MS) and gas chromatography / mass spectrometry (GC-MS) methods for analysis of the metabolites in AECOPD patients and compare the metabolites profiles between patients with systemic glucocorticoid treatment success and treatment failure.

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2024-02-01
Completion
2024-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04710849 on ClinicalTrials.gov